Will Popular’s (BPOP) Expanded $1 Billion Buyback Authorization Change Its Narrative?

Simply Wall St.
07-19
  • Earlier this week, Popular, Inc. announced an increase in its quarterly dividend from US$0.70 to US$0.75 per share, starting with the fourth quarter of 2025, alongside a US$500 million expansion of its share buyback plan, raising the total buyback authorization to US$1 billion contingent upon board approval.
  • This dual step signals both strong capital generation and management’s intent to return more value to shareholders through higher dividends and additional share repurchases.
  • We'll explore how the expanded US$1 billion buyback authorization could affect Popular’s investment outlook and shareholder value story.

Uncover 17 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

Advertisement

Popular Investment Narrative Recap

To own shares of Popular, Inc., you ultimately need to believe in its ability to generate consistent capital, navigate economic cycles in Puerto Rico and the U.S., and manage leadership transitions smoothly. The recently announced higher dividend and expanded buyback program reinforce Popular’s commitment to capital returns, but they do not materially change the most critical short-term catalyst, leadership transition, or the main risk, exposure to macroeconomic volatility and local challenges impacting growth.

Among the most relevant updates, the recent appointment of Javier D. Ferrer as CEO and director underscores that leadership change is moving forward as planned. Continuity and experience in management could help frame investor sentiment at a time when stable execution is key, especially as the company implements its enhanced capital return initiatives.

However, investors should keep in mind that, despite the recent focus on shareholder returns, the effects of local economic disruptions in Puerto Rico remain an important risk that could affect...

Read the full narrative on Popular (it's free!)

Popular's outlook anticipates $3.6 billion in revenue and $842.5 million in earnings by 2028. This projection is based on an annual revenue growth rate of 9.7% and represents a $155.5 million increase in earnings from the current $687.0 million.

Uncover how Popular's forecasts yield a $114.43 fair value, in line with its current price.

Exploring Other Perspectives

BPOP Community Fair Values as at Jul 2025

Fair value estimates from three Simply Wall St Community members for Popular, Inc. range from US$114.43 to US$243.49. As you compare these differing views, remember that ongoing leadership changes may significantly influence how investors weigh both risk and possible future performance.

Explore 3 other fair value estimates on Popular - why the stock might be worth over 2x more than the current price!

Build Your Own Popular Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

  • A great starting point for your Popular research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
  • Our free Popular research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Popular's overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

  • The end of cancer? These 25 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
  • The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
  • AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10